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Introduction
There is considerable debate over what should be chosen as a safe lower limit for blood glucose concentration in the neonatal period. [1] [2] [3] Glucose is the principal substrate for cerebral metabolism, and neonatal hypoglycaemia can cause damage to both neuronal and glial cells, resulting in severe handicap or death.i9 Nevertheless, newborn infants have been regarded as fairly resistant to the pathophysiological effects of hypoglycaemia because they often remain asymptomatic at blood glucose concentrations low enough to cause severe symptoms in adults.8'3 Such asymptomatic hypoglycaemia has been claimed to have a good prognosis,' 1418 suggesting that alternative metabolic substrates for the brain may be available in early life. 3 To exclude the possibility that asymptomatic and moderate hypoglycaemia may cause persistent adverse effects on neurodevelopment, however, requires large numbers of subjects, and available data do not provide adequate reassurance, particularly in infants born before term, in whom hypoglycaemia is common.'9 20 We examined the incidence and antecedents of low blood glucose concentrations in 661 infants of low birth weight and related the occurrence and persistence of hypoglycaemia to the neurodevelopmental outcome at 18 months after term in 543 survivors.
Subjects and methods
We studied 661 preterm infants who weighed less than 1850 g at birth and survived the first 48 hours of life. Their mean (SD) birth weight was 1337 (315) g, and their mean gestational age was 30 5 (2 7) weeks; those with major congenital abnormalities were excluded. The infants, who were taking part in a large study of feeding conducted at five centres,2' were a major unselected subsample of those for whom plasma glucose monitoring had been planned. Extensive demographic, obstetric, and neonatal data were available.
Weekly plasma samples were taken from the infants and analysed for glucose. In addition, glucose concentrations were determined with reagent sticks every six hours for the first 48-72 hours. Generally, infants with a blood glucose concentration on stick testing below 1 5 mmol/l or with two or more values below 2 0-2 5 mmol/l received a blood test to determine their plasma glucose concentration. All infants requiring intensive care (most of them) were monitored daily for plasma glucose concentration, regardless of the values on stick testing. This daily sampling continued until the infant was clinically stable, often into the second or third week. Only data from the plasma samples are reported in this study; these samples were analysed by the glucose oxidase method. Data from 6808 samples taken on separate days are presented. The study continued until the infants were discharged or weighed 2000 g, whichever occurred first. All infants were studied in the first week; the number still remaining in the study declined with postnatal age, falling to 428, 260, 127, and 59 infants by the third, fifth, seventh, and ninth weeks respectively.
Early feeding practices in the centres were broadly similar. Enteral feeding started before 2 hours in large, well babies, and in ill babies and those not tolerating feeds an intravenous infusion of glucose was established immediately, progressing within 48 hours to an incremental regimen to provide total parenteral nutrition. In four of the units intravenous nutrition was accompanied by minimal enteral feeding as soon as the infant's condition was stable. In one unit (centre B), however, small, sick babies usually had elective intravenous nutrition without enteral feeds for about two weeks. Hypoglycaemia was treated by increasing the rate of delivery of glucose; in addition, an initial bolus of glucose was given when the plasma glucose concentration was <1-0 mmol/l or thought to be causing symptoms and when hypoglycaemia was associated with an episode of acute asphyxia. respectively. This potential for underdiagnosis, however, was offset by the likelihood that hypoglycaemia occurred principally in small, sick infants, who were the ones monitored intensively. Table II shows that among the five centres studied the percentage of infants with plasma glucose concentrations <2 6 mmol/l that persisted on three or more days varied 10-fold (from 4% to 31%). In centres B and D (comparable regional referral units) the values were 6% (9/156 cases) and 21% (59/279 cases) (p<0-0001). In those infants with hypoglycaemia (plasma glucose concentration <2-6 mmol/l) the median age at onset was 2 days (range 1 to 58 days) and the median age when the final value <2-6 mmol/l was recorded was 6 days (range 1 to 91 days); such hypoglycaemia was detected beyond 1 month in 60 infants (nearly 10% of the cohort studied) and beyond two months in 16 infants. Only 31 infants had hypoglycaemia on three or more consecutive days; thus most of the infants with protracted hypoglycaemia had recurrent episodes.
FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HYPOGLYCAEMIA
Regression models were constructed to examine a range of factors associated with the occurrence of hypoglycaemia or the number of days on which it was recorded (dependent variable) with cut off points of either 1 5 or 2 5 mmol glucose/l. Significant factors (p<0-01) included the centre to which the infant was admitted, a birth weight under 1000 g, a 5 minute Apgar score <5, and being small for gestational age. After adjustment for other factors we found that social class, maternal toxaemia, maternal fatness (body mass index -that is, weight/(height)2), the infant's sex, and the infant's diet were not associated with hypoglycaemia (p>005). Gestational diabetes (requiring or not requiring insulin) occurred in only 11 cases, and no infant developed a plasma glucose concentration of <1 5 mmol/l, perhaps reflecting the preventive measures taken in this known high risk group. Infants who developed hypoglycaemia to any extent had a smaller body mass index at birth than those who did not-for instance, with 1 5 mmol/l as the cut off the mean (SE) body mass index was 8-6 (0-05) kg/m2 compared with 7 9 (0-11) kg/m2 (p<0-001).
SYMPTOMATIC AND ASYMPTOMATIC HYPOGLYCAEMIA
Of the 433 infants with a plasma glucose concentration <2 6 mmol/l, 222 had one or more of the following symptoms, which have been associated with hypoglycaemia': recurrent apnoea (164), vomiting (93), "jitteriness" (19) , and convulsions (13) . These symptoms, however, were found to be equally prevalent in the 228 infants without hypoglycaemia at equivalent postnatal age and after adjustment for birth weight and respiratory illness. In only five cases, in which hypoglycaemia was associated with fits, was there a convincing causal relation. Analysis of whether symptomatic infants had more neurodevelopmental problems at 18 months (see below) was confounded by the small number of asymptomatic infants with prolonged hypoglycaemia.
DEVELOPMENTAL SCORES AT I 8 MONTHS
Regression analysis was used to explore a minimum safe plasma glucose concentration in terms of developmental scores at 18 months (corrected age). The Bayley motor and mental development scales (dependent variables) were regressed against days ofhypoglycaemia (independent variable) with cut offs for plasma glucose concentrations between 0-5 and 4-0 mmol/l. Further independent variables were introduced to adjust for the infants' sex, gestational age (24- Further modelling showed that reduced developmental scores were associated independently with the number ofdays on which plasma glucose concentration was 0-1-5 mmol/l (p<0-01) and the number of days on which it was 1-6-2-5 mmol/l (p<0-01), whereas no relation was detected when it was in the range 2-6-4-0 mmol/l. For subsequent analyses a plasma glucose concentration of <2-6 mmol/l was used to define hypoglycaemia in preterm infants. Data from infants without cerebral palsy showed a progressive fall in developmental scores with increasing number of days on which hypoglycaemia was recorded. When infants with no hypoglycaemia were compared with those exhibiting it on five or more days the mean (SE) scores were 96-1 (1-3) v 84-4 (3-2) (p<0 001) for motor development and 102-0 (1 5) v 85-6 (3 7) (p<0 005) for mental development.
The slopes and 95% confidence intervals for the relation between the number of days on which hypoglycaemia was recorded and either motor development (p<0002) or mental development (p<0005) were defined by regression analysis (figure). The best fit was for developmental scores regressed against the logarithm of days of hypoglycaemia. More detailed analysis showed that when hypoglycaemia had been recorded on three or more days a significant effect on development was detectable and that frequent, moderate hypoglycaemia was associated with a greater developmental deficit than more severe but less frequent hypoglycaemia.
Exploration of interaction effects showed that social class and the mother's standard of education were related to mental (not motor) development independently of hypoglycaemia, and thus the association between hypoglycaemia and poor mental development was not ameliorated if the child came from a high social class background with a well educated mother. Respiratory illness and hypoglycaemia had independent, and hence additive, adverse effects on development. Birth weight, length of gestation, and fetal growth retardation did not influence the developmental vulnerability of preterm infants to hypoglycaemia; the age at onset of hypoglycaemia did not influence outcome. The reduction in motor scores with hypoglycaemia was identical in the non-intensively and intensively monitored groups (p<0-02 in both groups), though there was a trend towards a greater reduction in mental score in those monitored intensively (p<001 in this group). Overall, however, these data suggested that despite the inevitably greater number of samples obtained from sick, smaller infants the relation between hypoglycaemia and reduced scores was not fundamentally altered by this sampling bias. When data from the three largest centres (B, C, and D) were analysed separately (table V) motor and mental developmental scores after five or more days of hypoglycaemia were reduced (only the reduction in mental development in centre D failed to reach significance). There was a small sampling bias among centres: in centres C, B, and D the proportion of infants who had their glucose concentrations determined five or more times was 59%, 62%, and 79% respectively. This ranking was not, however, the same as that for the magnitude of reduction in developmental scores in these centres (table IV) or for the proportion of infants in each centre with hypoglycaemia for three or more days (table II) . There were too few infants from centres A and E for analysis by individual centre.
Centres B and D conducted routine cerebral ultrasound investigations. We performed a two centre analysis to exclude the possibility that a differential occurrence of parenchymal haemorrhage or intraventricular haemorrhage with ventricular dilatation had confounded our findings as such intracerebral disease might be expected to have a major effect on development. After adjustment for this additional variable the relation between hypoglycaemia and reduced developmental scores or neurodevelopmental impairment was unchanged.
Discussion
We showed in a large five centre study that pronounced hypoglycaemia (plasma glucose concentration < 1 -6 mmol/l), which occurred in 28% ofinfants whose birth weight was under 1850 g, is now more common in premature babies than was reported 10-20 years ago.'920 Furthermore, moderate hypoglycaemia (plasma glucose concentration under 2-6 mmol/l), which is often disregarded, occurred in 67% of infants, often over prolonged periods (table I) , and our data show that even moderate hypoglycaemia is associated with a considerable increase in adverse neurodevelopmental sequelae.
Important hypoglycaemia is commonly said to occur when the plasma glucose concentration is under 1-4 mmol/I in preterm or low birthweight infants in the first week, under 1-9 mmoL/l in term infants during the first 72 hours, and under 2-6 mmol/l thereafter.' Such values imply that preterm infants are less prone to hypoglycaemic neurological impairment than term infants, that resistance to such damage is greatest during the immediate postpartum period, and that neonates are less prone to damage than adults. None of these contentions has been adequately supported by data on neurodevelopmental outcome. In this study there was no evidence that birth weight, length of gestation, or postnatal age influenced the observed relation between hypoglycaemia and poor developmental outcome.
Plasma glucose concentrations below 2-6 mmol/l were associated with reductions in Bayley motor and mental development scores at 18 months, even after adjustment for confounding factors known to influence development. This deficit increased with days of hypoglycaemia at this concentration. It was not possible to obtain daily blood samples throughout the infants' hospital stay, and in some infants in whom hypoglycaemia was recorded on more than five separate days sampling was intermittent. Thus we could not define the precise relation between neurodevelopment and hypoglycaemia when this occurred on more than five days. Nevertheless, when all infants with a plasma glucose concentration under 2 -6 mmol/l on five or more days were compared with infants without hypoglycaemia reductions in mental and motor development scores of 14 and 13 points respectively were observed, even after adjustment for confounders. We showed that there was a significant reduction in scores after hypoglycaemia on three to four days; a large sample size would be needed, however, to detect whether this was so after one or two days of hypoglycaemia.
The importance ofsuch a large reduction in developmental scores at 18 months may be questioned. The predictive value of such early tests in general and the potential for catch up development in infants who develop hypoglycaemia are not well defined, yet some data indicate that Bayley scores at 18 months correlate with intelligence quotients measured later,23 perhaps more convincingly in populations than in individual subjects. This cohort will be assessed again later, when these issues should be largely resolved. Though some uncertainty remains, our finding that when a plasma glucose concentration below 2 6 mmol/l was recorded on five days or more it was associated with a substantially increased risk (3 5- Although several studies have emphasised the difference in prognosis between symptomatic and asymptomatic hypoglycaemia,48-'0'4'6 our data show the difficulty in making this distinction in infants receiving neonatal intensive care. Half of the infants with plasma glucose concentrations under 2 6 mmol/l had concurrent apnoea, vomiting, jitteriness, or fits; yet an almost identical proportion of babies without hypoglycaemia had the same symptoms. In very few of the hypoglycaemic infants could the associated symptoms be related convincingly to low plasma glucose concentration.
Factors that we found to be associated with hypoglycaemia, including low birth weight, fetal growth retardation, and low Apgar scores, were predictable,'9 1920 but the high overall incidence of hypoglycaemia and the number of days on which it occurred were surprising. Several authors have noted the incidence of hypoglycaemia in low birthweight infants.'920245 Lubchenco and Bard reported that 15% of preterm infants of appropriate size for their gestational age had a serum glucose concentration under 17 mmol/l'9; yet Gutberlet and Cornblath reported that only 16% of infants below 2500 g became hypoglycaemic.20 With a comparable cut off for plasma glucose concentration (under 1 6 mmol/l) we found that the incidence of hypoglycaemia in preterm babies who were the appropriate size for their gestational age was 26%, perhaps reflecting the increased proportion of extremely low birthweight infants in our cohort. There is little information, however, with which to compare our data for more moderate hypoglycaemia (<2-6 mmol/l); its high incidence, with 24% of infants having it on three to 30 separate days and 14% having it beyond one month of age, was not expected. Moreover, because sampling was discontinuous in this study our data are probably an underestimate of the true incidence and duration.
This multicentre study perhaps identified a prevailing view among neonatologists that plasma glucose concentrations in the range 15-2*5 mmolIl are of doubtful importance in early life. Nevertheless, the great variation in the number of days on which hypoglycaemia was observed among comparable centres indicates a major inconsistency in the approach to management. Although some paediatricians might regard correction of this degree of hypoglycaemia as excessive, most preterm infants in this study developed hypoglycaemia early, when they still had intravascular lines that would have facilitated accurate control of blood glucose concentrations. We suggest that the data on neurodevelopment presented here indicate an urgent need to reappraise the management of neonatal hypoglycaemia. Because gestational age did not influence the relation between hypoglycaemia and impaired neurodevelopment our conclusions may apply also to the full term neonates. Although further follow up of our cohort will enable us to establish the longer term importance of these findings, it would --;se not to allow plasma glucose concentrations in prnzerm, and perhaps full term, infants to remain below 2 6 mmol/l.
